Challenges in the development of bispecific antibodies for non-Hodgkin lymphoma
Mené sur 145 patients atteints d'un lymphome non hodgkinien à cellules B réfractaire ou récidivant (âge médian : 67 ans ; durée médiane de suivi : 4,2 mois), cet essai de phase I évalue la dose maximale tolérée de l'odronextamab, un anticorps bispécifique ciblant CD3 (sur les cellules T) et ciblant CD20 (sur les cellules B) en monothérapie, et son efficacité, du point de vue du taux de réponse objective
In The Lancet Haematology, Rajat Bannerji and colleagues report the results of an ongoing phase 1 trial of the CD20×CD3 bispecific antibody,odronextamab, in B-cell non-Hodgkin lymphoma. CD3-bispecific antibodies work by forminga trimer that involves T cells and a surface antigen on the target cell, in this case,CD20 on malignant and non-malignant B-lymphocytes. Human leukocyte antigen (HLA)-independentactivation of polyclonal T cells leads to lysis of the target cell. A secondary expansionof T-cell subsets and induction of inflammatory cytokines might follow, contributing to the clinical response and primary dose-limiting toxicity of cytokinerelease syndrome.
The Lancet Haematology , commentaire, 2021